The July 2003 approval of biosynthetic growth hormone (GH) by the Food and Drug Administration (FDA) for treating children with idiopathic short stature1 has raised questions from physicians, parents, and the media about the appropriate use of this treatment and the effect of this decision on US children.2,3 This editorial reviews the implications of the new GH indication for pediatric practice and policy.
Cuttler L, Silvers JB. Growth Hormone Treatment for Idiopathic Short StatureImplications for Practice and Policy. Arch Pediatr Adolesc Med. 2004;158(2):108-110. doi:10.1001/archpedi.158.2.108